LON:HEMO Hemogenyx Pharmaceuticals (HEMO) Share Price, News & Analysis GBX 621 -69.50 (-10.07%) As of 11:58 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsNews and Trends About Hemogenyx Pharmaceuticals Stock (LON:HEMO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HEMO alerts:Sign Up Key Stats Today's Range 621▼ 69050-Day Range 437▼ 75552-Week Range 356▼ 1,220Volume5,624 shsAverage Volume22,710 shsMarket Capitalization£42.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom. Read More Receive HEMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemogenyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HEMO Stock News HeadlinesHemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious AwardNovember 19 at 6:17 PM | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces First Patient Treated in Second Adult Dose CohortNovember 12, 2026 | finance.yahoo.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 20 at 1:00 AM | Profits Run (Ad)Hemogenyx Pharmaceuticals (LON:HEMO) Stock Price Down 0.9% - Here's WhyNovember 10, 2026 | americanbankingnews.comHemogenyx Pharmaceuticals PLC Announces Feasibility Study AgreementOctober 19, 2026 | finance.yahoo.comHemogenyx Pharmaceuticals Plc veröffentlicht Ergebnisse für das Halbjahr zum 30. Juni 2026September 29, 2026 | de.marketscreener.comDHemogenyx Pharmaceuticals Plc Reports Earnings Results for the Half Year Ended June 30, 2026September 28, 2026 | marketscreener.comMHemogenyx Advances HG-CT-1 AML Trial as First-Half Loss Reaches £6.56 MillionSeptember 28, 2026 | uk.finance.yahoo.comSee More Headlines HEMO Stock Analysis - Frequently Asked Questions How have HEMO shares performed this year? Hemogenyx Pharmaceuticals' stock was trading at GBX 578 at the start of the year. Since then, HEMO shares have increased by 7.4% and is now trading at GBX 621. How were Hemogenyx Pharmaceuticals' earnings last quarter? Hemogenyx Pharmaceuticals Plc (LON:HEMO) announced its quarterly earnings results on Monday, September, 28th. The company reported GBX (101.70) earnings per share for the quarter. How do I buy shares of Hemogenyx Pharmaceuticals? Shares of HEMO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Hemogenyx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hemogenyx Pharmaceuticals investors own include International Consolidated Airlines Group (IAG), Supply@ME Capital (SYME), Aurora Cannabis (ACB), AIM ImmunoTech (AIM), American Battery Technology (ABML), AiAdvertising (AIAD) and Abingdon Health (ABDX). Company Calendar Last Earnings9/28/2026Today11/20/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:HEMO Previous SymbolLON:SILF CIKN/A Websilverfalconplc.com Phone44 79 0917 7311FaxN/AEmployees14Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (130.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£6.89 thousand Net MarginsN/A Pretax MarginN/A Return on Equity-409.57% Return on Assets-37.79% Debt Debt-to-Equity Ratio42.86 Current Ratio4.04 Quick Ratio6.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 303.67 per share Price / Cash Flow2.05 Book ValueGBX 0.25 per share Price / Book2,520.71Miscellaneous Outstanding Shares6,897,000Free FloatN/AMarket Cap£42.83 million OptionableNot Optionable Beta1.49 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (LON:HEMO) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersAre Tesla and SpaceX Going Bankrupt?Tesla and SpaceX shares crashed right after Democrats took the House and the Senate in the midterm election. E...Brownstone Research | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemogenyx Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemogenyx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.